4D Molecular Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 21, 2024, details the results of the 2024 Annual Meeting of Stockholders held virtually by 4D Molecular Therapeutics, Inc. The meeting addressed the election of directors and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
As of the record date (April 3, 2024), there were 51,157,472 shares of common stock outstanding. A total of 45,054,713 shares were voted at the meeting. The following proposals were approved:
- Proposal 1 (Election of Director): David Kirn, M.D. was elected as a Class I director to serve until the 2027 Annual Meeting.
- For: 35,630,613 votes
- Withheld: 7,849,441 votes
- Broker Non-Votes: 1,574,659 votes
- Proposal 2 (Ratification of Auditor): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- For: 45,032,000 votes
- Against: 21,052 votes
- Abstain: 1,661 votes
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder vote.
Key Facts for Investor Verification
- David Kirn, M.D. has been elected to the Board of Directors for a term ending in 2027.
- PricewaterhouseCoopers LLP has been ratified as the independent auditor for the 2024 fiscal year.
- Approximately 88% of outstanding shares were voted at the Annual Meeting.
- Over 99% of votes cast on the auditor ratification proposal were in favor.